Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.41 |
| ▸ | TRAP1 | Q12931 | 4/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.35 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
| ▸ | PRKACA | P17612 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.33 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581866 | 0.80 | ELANE (0.38) | ELANEFAAHPOLB | |
| SCHEMBL4458924 | 0.78 | TRAP1 (0.40) | ADAHSP90AA1HSP90AB1TRAP1SLC2A1 | |
| SCHEMBL4454416 | 0.77 | ADORA2A (0.59) | ADORA2AADORA1HDAC1 | |
| SCHEMBL1128374 | 0.77 | PIK3CA (0.56) | PIK3CA | |
| SCHEMBL17403259 | 0.76 | ROCK2 (0.41) | ADAHSP90AA1HSP90AB1ELANEFAAH | |
| SCHEMBL18171860 | 0.73 | POLB (0.38) | ELANEFAAHPOLBROCK2CHEK2 | |
| SCHEMBL31106018 | 0.72 | ROCK2 (0.41) | HSP90AA1HSP90AB1ELANEFAAHSLC2A1 | |
| SCHEMBL3607614 | 0.72 | ELANE (0.37) | HSP90AA1HSP90AB1ELANEFAAHHDAC1 | |
| SCHEMBL22772812 | 0.71 | ELANE (0.38) | HSP90AA1HSP90AB1ELANEFAAHPOLB | |
| SCHEMBL3989629 | 0.70 | PIK3CA (0.49) | PIK3CAHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629349-B2 | Pyrazolo [3,4-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| EP-1349552-B1 | PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2008-08-20 | — | — | EP | disclosed |
| US-7087754-B2 | Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2006-08-08 | — | — | US | disclosed |
| US-20060111373-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED | 2006-05-25 | — | — | US | disclosed |
| US-20040116447-A1 | Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111373-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | CHRNA6, CHRNA5, CNR1 | ADA 1023/4885HSP90AA1 4561/4885HSP90AB1 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.